Scienza e Tecnologia
Rinri Therapeutics Appoints Terri Gaskell, PhD as Chief Technology Officer
SHEFFIELD, England , Dec. 17, 2020 /PRNewswire/ -- Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announced the appointment of Dr. Terri Gaskell as its Chief Technology Officer (CTO) and member of the executive team. Dr. Gaskell brings over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
Terri joins from the UK Cell and Gene Therapy Catapult (CGTC) where she has worked for over seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role at CGTC also included advising academics and small companies on the development of advanced therapies.
Prior to this, Terri held senior roles at Cell Guidance Systems and Cellartis AB (now Takara Bio Europe AB) where she was focussed on the development of processes for the expansion and differentiation of pluripotent stem cells for therapeutic use and drug discovery.
Terri received her Bachelor of Science (BSc.) (Hons) in Biochemistry from the University of Dundee and holds a PhD in Cell and Molecular Biology from the University of Edinburgh .
, said: " "
said: " "
Rinri Therapeutics is a private biotechnology company developing advanced stem cell-based therapeutics to restore hearing. The company's pioneering technology seeks to reverse sensorineural hearing loss (SNHL) through the repair of the damaged cytoarchitecture in the inner ear. SNHL is estimated to affect 64 million patients in the US and 34 million in Europe . There are currently no pharmacological treatment options for SNHL patients.
Rinri, is backed by Boehringer Ingelheim Venture Fund (BIVF), UCB Ventures, BioCity and the University of Sheffield . Rinri was founded in late-2018 and is headquartered in Sheffield, UK .
For more information, please visit: www.rinri-therapeutics.com
Rinri Therapeutics
Dr Simon Chandler , CEO
admin@rinri-therapeutics.com
Citigate Dewe Rogerson
Sylvie Berrebi , Frazer Hall
rinri@citigatedewerogerson.com
T: +44 (0)20 7638 9571